Brexpiprazole, sold under the brand name Rexulti among others, is a medication used for the treatment of major depressive disorder, schizophrenia, and agitation associated with dementia due to Alzheimer's disease.[11][13][14] It is an atypical antipsychotic.[11]
The most common side effects include akathisia (a constant urge to move) and weight gain.[12] The most common side effects among people with agitation associated with dementia due to Alzheimer's disease include headache, dizziness, urinary tract infection, nasopharyngitis, and sleep disturbances (both somnolence and insomnia).[13]
Brexpiprazole was developed by Otsuka and Lundbeck, and is considered to be a successor to aripiprazole (Abilify).[15] It was approved for medical use in the United States in July 2015.[16][17] A generic version was approved in August 2022.[18] Brexpiprazole is the first treatment approved by the US Food and Drug Administration (FDA) for agitation associated with dementia due to Alzheimer's disease.[13]
^"Brexpiprazole (Rexulti) Use During Pregnancy". Drugs.com. 10 February 2020. Retrieved 18 August 2020.
^ ab"Rexulti brexpiprazole 4 mg film coated tablets blisters (273224)". Therapeutic Goods Administration (TGA). Retrieved 26 February 2023.
^"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
^AusPAR: Brexpiprazole
^"Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 April 2023.
^"Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.
^Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
^"Rexulti Product information". Health Canada. Retrieved 26 February 2023.
^Rexulti monograph
^"Mental health". Health Canada. 9 May 2018. Retrieved 13 April 2024.
^ abcd"Rexulti- brexpiprazole tablet Rexulti- brexpiprazole kit". DailyMed. 21 February 2023. Retrieved 26 February 2023.
^ ab"Rxulti EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 26 February 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ abc"FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer's Disease". U.S. Food and Drug Administration (FDA) (Press release). 11 May 2023. Retrieved 12 May 2023. This article incorporates text from this source, which is in the public domain.
^Lee D, Slomkowski M, Hefting N, Chen D, Larsen KG, Kohegyi E, et al. (December 2023). "Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial". JAMA Neurology. 80 (12): 1307–1316. doi:10.1001/jamaneurol.2023.3810. PMC 10628834. PMID 37930669.
^"Otsuka HD places top priority on development of OPC-34712". Chemical Business Newsbase. 3 January 2011. Retrieved 10 February 2012.
^"Rexulti (brexpiprazole) Tablets". U.S. Food and Drug Administration (FDA). 10 July 2015. Retrieved 18 August 2020.
^"FDA approves new drug to treat schizophrenia and as an add on to an antidepressant to treat ]" (Press release). U.S. Food and Drug Administration (FDA). 13 July 2015. Archived from the original on 15 July 2015. Retrieved 14 July 2015.
^"2022 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). 3 March 2023. Retrieved 30 April 2023.
Brexpiprazole, sold under the brand name Rexulti among others, is a medication used for the treatment of major depressive disorder, schizophrenia, and...
vilazodone. It is similar to the marketing strategy used for the drug brexpiprazole, labeling it as a "serotonin-dopamine activity modulator" or 'SDAM'...
dopamine and serotonin receptors. The drug is also related structurally to brexpiprazole and cariprazine. In October 2023, Reviva Pharmaceuticals released topline...
(Abilify) – approved as an adjunct to antidepressant for major depression Brexpiprazole (Rexulti) – approved as an adjunct to antidepressant for major depression...
control/addictive behaviors such as habitual self-mutilation Rexulti (brexpiprazole) – atypical antipsychotic used to treat mood and psychotic disorders...
adding on the atypical antipsychotic brexpiprazole for short-term or acute management may be considered. Brexpiprazole may be effective for some people,...
Modafinil - The (R)-(−)-enantiomer, known as Armodafinil in its pure form Brexpiprazole Cariprazine Cannabidiol GSK-789,472 – Also D3 antagonist, with good...
(schizophrenia and bipolar 1). Lundbeck manufactures drugs such as: Brexpiprazole for Alzheimer's disease, bipolar disease and PTSD Foliglurax for Parkinson's...
Global Information
This article incorporates text from this source, which is in the public domain.
